Nasus Pharma (NSRX) CEO issues 2025 shareholder letter via 6-K filing

Rhea-AI Filing Summary

Nasus Pharma Ltd. furnished a Form 6-K to provide investors with a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders.” The press release, dated December 22, 2025, is attached as Exhibit 99.1 and contains the CEO’s 2025 shareholder letter.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On December 22, 2025, Nasus Pharma Ltd. (the “Company”) issued a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release issued on December 22, 2025 by Nasus Pharma Ltd. titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		NASUS PHARMA LTD.
Date:	December 22, 2025	By:	/s/ Dan Teleman
		Name:	Dan Teleman
		Title:	Chief Executive Officer

FAQ

What did Nasus Pharma Ltd. (NSRX) report in its December 2025 Form 6-K?

Nasus Pharma Ltd. filed a Form 6-K to furnish a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders.” The press release, dated December 22, 2025, is included as Exhibit 99.1 to the report.

What is Exhibit 99.1 in Nasus Pharma Ltd. (NSRX) December 2025 Form 6-K?

Exhibit 99.1 is a press release issued by Nasus Pharma Ltd. on December 22, 2025 titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders.” It contains the contents of the CEO’s 2025 letter to shareholders.

When was the Nasus Pharma Ltd. (NSRX) CEO 2025 shareholder letter issued?

The CEO’s 2025 shareholder letter from Nasus Pharma Ltd. was issued via press release on December 22, 2025. This press release is attached to the Form 6-K filing as Exhibit 99.1.

Why did Nasus Pharma Ltd. (NSRX) submit this Form 6-K?

Nasus Pharma submitted this Form 6-K to formally furnish a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders.” The filing makes the CEO’s 2025 shareholder letter publicly available as Exhibit 99.1.

Who signed Nasus Pharma Ltd. (NSRX) December 2025 Form 6-K?

The Form 6-K was signed on behalf of Nasus Pharma Ltd. by Dan Teleman, the company’s Chief Executive Officer, dated December 22, 2025, confirming the report was authorized by management.

Does Nasus Pharma Ltd. (NSRX) file annual reports on Form 20-F or Form 40-F?

The Form 6-K indicates that Nasus Pharma Ltd. files or will file its annual reports under cover of Form 20-F, which is the standard annual report format for foreign private issuers on U.S. exchanges.